MedPath

Prazosin

Generic Name
Prazosin
Brand Names
Minipress, Minizide
Drug Type
Small Molecule
Chemical Formula
C19H21N5O4
CAS Number
19216-56-9
Unique Ingredient Identifier
XM03YJ541D

Overview

Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.

Background

Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.

Indication

This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents . Prazosin does not negatively impact lung function, and therefore may be used to manage hypertension in patients who are asthmatic or patients with chronic obstructive lung disease (COPD).

Associated Conditions

  • Agitation
  • Benign Prostatic Hyperplasia (BPH)
  • Hypertension
  • Raynaud's Phenomenon
  • Disturbed sleep/nightmares

FDA Approved Products

Prazosin Hydrochloride
Manufacturer:Granules Pharmaceuticals Inc.
Route:ORAL
Strength:2 mg in 1 1
Approved: 2023/01/27
NDC:70010-085
Prazosin Hydrochloride
Manufacturer:Granules Pharmaceuticals Inc.
Route:ORAL
Strength:1 mg in 1 1
Approved: 2023/01/27
NDC:70010-084
prazosin hydrochloride
Manufacturer:Proficient Rx LP
Route:ORAL
Strength:2 mg in 1 1
Approved: 2023/10/01
NDC:82804-021
Prazosin Hydrochloride
Manufacturer:Prasco Laboratories
Route:ORAL
Strength:1 mg in 1 1
Approved: 2023/03/27
NDC:66993-431
Prazosin Hydrochloride
Manufacturer:Prasco Laboratories
Route:ORAL
Strength:2 mg in 1 1
Approved: 2023/03/27
NDC:66993-432

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath